Opportunistic infections studies update.
Walker
M J
MJ
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000666:Amphotericin B / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D053626:Atovaquone; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003457:Cryptosporidiosis / Q000150:complications / Q000188:drug therapy; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy; D009285:Naphthoquinones / Q000627:therapeutic use; D010303:Paromomycin / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000517:prevention & control; D011739:Pyrimethamine / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000150:complications / Q000188:drug therapy; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy
D000995:Antitubercular Agents; D009285:Naphthoquinones; D010303:Paromomycin; D000666:Amphotericin B; D015774:Ganciclovir; D053626:Atovaquone; D011739:Pyrimethamine